124 related articles for article (PubMed ID: 32504550)
1. Neratinib decreases pro-survival responses of [sorafenib + vorinostat] in pancreatic cancer.
Booth L; Poklepovic A; Dent P
Biochem Pharmacol; 2020 Aug; 178():114067. PubMed ID: 32504550
[TBL] [Abstract][Full Text] [Related]
2. Prior exposure of pancreatic tumors to [sorafenib + vorinostat] enhances the efficacy of an anti-PD-1 antibody.
Booth L; Roberts JL; Poklepovic A; Dent P
Cancer Biol Ther; 2019; 20(1):109-121. PubMed ID: 30142009
[TBL] [Abstract][Full Text] [Related]
3. The irreversible ERBB1/2/4 inhibitor neratinib interacts with the BCL-2 inhibitor venetoclax to kill mammary cancer cells.
Booth L; Roberts JL; Avogadri-Connors F; Cutler RE; Lalani AS; Poklepovic A; Dent P
Cancer Biol Ther; 2018 Mar; 19(3):239-247. PubMed ID: 29333953
[TBL] [Abstract][Full Text] [Related]
4. Neratinib and entinostat combine to rapidly reduce the expression of K-RAS, N-RAS, Gα
Booth L; Roberts JL; Sander C; Lalani AS; Kirkwood JM; Hancock JF; Poklepovic A; Dent P
Cancer Biol Ther; 2019; 20(5):700-710. PubMed ID: 30571927
[TBL] [Abstract][Full Text] [Related]
5. Neratinib kills B-RAF V600E melanoma via ROS-dependent autophagosome formation and death receptor signaling.
Dent P; Booth L; Poklepovic A; Kirkwood JM
Pigment Cell Melanoma Res; 2022 Jan; 35(1):66-77. PubMed ID: 34482636
[TBL] [Abstract][Full Text] [Related]
6. Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation.
Park MA; Zhang G; Martin AP; Hamed H; Mitchell C; Hylemon PB; Graf M; Rahmani M; Ryan K; Liu X; Spiegel S; Norris J; Fisher PB; Grant S; Dent P
Cancer Biol Ther; 2008 Oct; 7(10):1648-62. PubMed ID: 18787411
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib and vorinostat kill colon cancer cells by CD95-dependent and -independent mechanisms.
Walker T; Mitchell C; Park MA; Yacoub A; Graf M; Rahmani M; Houghton PJ; Voelkel-Johnson C; Grant S; Dent P
Mol Pharmacol; 2009 Aug; 76(2):342-55. PubMed ID: 19483104
[TBL] [Abstract][Full Text] [Related]
8. The irreversible ERBB1/2/4 inhibitor neratinib interacts with the PARP1 inhibitor niraparib to kill ovarian cancer cells.
Booth L; Roberts JL; Samuel P; Avogadri-Connors F; Cutler RE; Lalani AS; Poklepovic A; Dent P
Cancer Biol Ther; 2018 Jun; 19(6):525-533. PubMed ID: 29405820
[TBL] [Abstract][Full Text] [Related]
9. BCL-2 family inhibitors enhance histone deacetylase inhibitor and sorafenib lethality via autophagy and overcome blockade of the extrinsic pathway to facilitate killing.
Martin AP; Park MA; Mitchell C; Walker T; Rahmani M; Thorburn A; Häussinger D; Reinehr R; Grant S; Dent P
Mol Pharmacol; 2009 Aug; 76(2):327-41. PubMed ID: 19483105
[TBL] [Abstract][Full Text] [Related]
10. The levels of mutant K-RAS and mutant N-RAS are rapidly reduced in a Beclin1 / ATG5 -dependent fashion by the irreversible ERBB1/2/4 inhibitor neratinib.
Booth L; Roberts JL; Poklepovic A; Kirkwood J; Sander C; Avogadri-Connors F; Cutler RE; Lalani AS; Dent P
Cancer Biol Ther; 2018 Feb; 19(2):132-137. PubMed ID: 29219657
[TBL] [Abstract][Full Text] [Related]
11. Enhanced signaling via ERBB3/PI3K plays a compensatory survival role in pancreatic tumor cells exposed to [neratinib + valproate].
Dent P; Booth L; Poklepovic A; Hoff DV; Hancock JF
Cell Signal; 2020 Apr; 68():109525. PubMed ID: 31911180
[TBL] [Abstract][Full Text] [Related]
12. Neratinib degrades MST4 via autophagy that reduces membrane stiffness and is essential for the inactivation of PI3K, ERK1/2, and YAP/TAZ signaling.
Dent P; Booth L; Poklepovic A; Martinez J; Hoff DV; Hancock JF
J Cell Physiol; 2020 Nov; 235(11):7889-7899. PubMed ID: 31912905
[TBL] [Abstract][Full Text] [Related]
13. Palbociclib augments Neratinib killing of tumor cells that is further enhanced by HDAC inhibition.
Booth L; Roberts JL; Rais R; Cutler RE; Diala I; Lalani AS; Poklepovic A; Dent P
Cancer Biol Ther; 2019; 20(2):157-168. PubMed ID: 30183517
[TBL] [Abstract][Full Text] [Related]
14. Neratinib augments the lethality of [regorafenib + sildenafil].
Booth L; Roberts JL; Rais R; Cutler RE; Diala I; Lalani AS; Hancock JF; Poklepovic A; Dent P
J Cell Physiol; 2019 Apr; 234(4):4874-4887. PubMed ID: 30203445
[TBL] [Abstract][Full Text] [Related]
15. Neratinib inhibits Hippo/YAP signaling, reduces mutant K-RAS expression, and kills pancreatic and blood cancer cells.
Dent P; Booth L; Roberts JL; Liu J; Poklepovic A; Lalani AS; Tuveson D; Martinez J; Hancock JF
Oncogene; 2019 Jul; 38(30):5890-5904. PubMed ID: 31253872
[TBL] [Abstract][Full Text] [Related]
16. The multi-kinase inhibitor lenvatinib interacts with the HDAC inhibitor entinostat to kill liver cancer cells.
Roberts JL; Poklepovic A; Booth L; Dent P
Cell Signal; 2020 Jun; 70():109573. PubMed ID: 32087304
[TBL] [Abstract][Full Text] [Related]
17. Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation.
Zhang G; Park MA; Mitchell C; Hamed H; Rahmani M; Martin AP; Curiel DT; Yacoub A; Graf M; Lee R; Roberts JD; Fisher PB; Grant S; Dent P
Clin Cancer Res; 2008 Sep; 14(17):5385-99. PubMed ID: 18765530
[TBL] [Abstract][Full Text] [Related]
18. The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib/dabrafenib-resistant melanoma cells in vitro and in vivo.
Booth L; Roberts JL; Sander C; Lee J; Kirkwood JM; Poklepovic A; Dent P
Oncotarget; 2017 Mar; 8(10):16367-16386. PubMed ID: 28146421
[TBL] [Abstract][Full Text] [Related]
19. Osimertinib-resistant NSCLC cells activate ERBB2 and YAP/TAZ and are killed by neratinib.
Dent P; Booth L; Poklepovic A; Von Hoff D; Martinez J; Zhou Y; Hancock JF
Biochem Pharmacol; 2021 Aug; 190():114642. PubMed ID: 34077739
[TBL] [Abstract][Full Text] [Related]
20. Sorafenib activates CD95 and promotes autophagy and cell death via Src family kinases in gastrointestinal tumor cells.
Park MA; Reinehr R; Häussinger D; Voelkel-Johnson C; Ogretmen B; Yacoub A; Grant S; Dent P
Mol Cancer Ther; 2010 Aug; 9(8):2220-31. PubMed ID: 20682655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
